- Professor Stephen Mahler
- Dr Martina Jones
- Nancy Eluigwe
- Professor Ross Barnard
- Associate Professor Mathias Francois
- Professor Peter Gray
- Dr Christopher Howard
- Professor Linda Lua
- Dr. Lucia Zacchi
- Dr Benjamin Schulz
- Professor Paul Young
- Dr Esteban Marcellin Saldana
- Dr Cristiana Dal’Molin
- Dr. Veronica Martinez Salazar
- Dr Xuan Bui
- Jessica Heinemann
- Mallory Daleris
- Dr Christian Fercher
- Dr Gary Shooter
- Professor Trent Munro
Professor Stephen Mahler specialises in research and development of biologic medicines.
Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. Professor Mahler is a biotechnologist with a focus on R&D of recombinant-DNA derived protein biopharmaceuticals, drug delivery systems and nanomedicines. Professor Mahler has a record of translational research success and engages extensively with industry associated with the biomedical sciences both nationally and internationally.
Research within CBI covers three thematic research areas; discovery of new biopharmaceuticals, engineering cells for production of protein-based biopharmaceuticals and advanced manufacturing for industrial production. A current research interest is at the interface of the life sciences and materials science, using a synthetic biology approach for creating novel therapeutic entities as well as new systems for drug delivery.
Professor Mahler has a strong interest in education and training and was formerly Head of the Chemical and Biological Engineering Plan at the University of Queensland (2010-2016). Other educational initiatives include development of Masters Programs and a Continuing Professional Development program in the area of biopharmaceuticals. The CPD program is available to stakeholders in the industry, both in Australia and internationally.
Nancy is a results-driven professional with over 10 years extensive experience in management and leadership positions.Her experience encompasses the areas of operational and strategic management, Human Resources management, financial management & reporting, industry engagement, business development, project management and delivery. Nancy is passionate about leadership and delivery of innovative research that is relevant to industry and building long-term strategic business partnerships in a challenging environment.
- Fellow of the Australian Society for Microbiology
- Doctor of Science, The University of Queensland
- Fellow of the National Academy of Clinical Biochem
- Postgraduate Diploma in Education, The University of Queensland
- Doctor of Philosophy, The University of Queensland
- Bachelor of Science (Hons), Monash University
- Bachelor of Science, University of Melbourne
- Doctor of Philosophy, Queensland University of Technology
POSTDOC - CSL CHARACTERISATION PROJECTSDr Lucía Zacchi is a molecular biologist and genetic engineer. Her research aims to characterize the molecular machinery involved in the secretory pathway and to engineer this machinery for biomedical and biotechnological applications. Her focus is on the processes of protein glycosylation, secretion, and degradation. She employs a variety of techniques, including mass spectrometry proteomics, genetics, biochemistry, and molecular biology to study mammalian cells, the model yeast Saccharomyces cerevisiae (Baker's yeast), and bodily fluids and organs. At CBI Dr Zacchi is engineering bioprocesses and cell lines to optimise the production of biotherapeutic glycoproteins. Dr Zacchi graduated from Universidad Nacional de Río Cuarto (Argentina) and the University of Minnesota (USA), and is a Fulbright and an Endeavour alumna.
QualificationsDoctor of Philosophy in Microbiology, Immunology and Cancer Biology, University of Minnesota
Current projects in my laboratory include:
- Structural biology based studies on the dengue virus proteins, NS3 (the viral protease) and E (a virion surface protein involved in cell binding and entry) and the RSV protein F (the viral fusion protein) as targets for antiviral drug design
- Sub-unit and DNA based vaccines for the dengue viruses
- Molecular pathogenesis of severe dengue disease (in particular, the consequences of dengue virus infection of host macrophages and the induction of mediators of vascular leak)
- Design and delivery of ribozymes (catalytic RNAs) to the respiratory tract as an antiviral strategy for RSV infections